GENERAL COMMENTS
Some major comments 1-They assessed fecal calprotectin but after we don't know for what, In their definition of clinical remission , this biomarker is not included. This point is important. In STORI study, fecal calprotectin was an independant factor (compared to CRP and CDEIS) to predict clinical relapse. Clarify 2-MRI : the authors defined mucosal healing by no signs of disease activity. referecebces related to this point are not reliable with this definition. Report Ordas Study (gastroenetrology wich define mucosal healing with Maria Score. In the design , it is reported Endoscopy and / or MRI and in the beginning of study design : colonoscopy or MRI : clarify 3) concomitant therapy with other immune suppressants is allowed. This point could biased resuts. We can think that descalation of IFX undercombotherpy (like STORI) is not the sale that descalation in patients treated by IFX monotherpy. This point must be discused. Strafie on IS? it could be a limitation of this study 4) Are patients optimised under IFX treatment included or only patients teated at 5mg/kg ? 5) It will be very difficult to included the number of patients planned in this study. STORI study included all patients only in clinical remission under combotherapy for at least 6 months . In this study included all GETAID centers from France and some belgium centers) , the time of inclusion was more than two yeras. In the study design, inclusion of patient with deep remission (clinical , biological and tissue) could be more difficult and a very large multicentric study could be usefull for perhaps obtain this number of patients.
It is a very important trial . We ned to investigate how to manage patients with CD in long term sustained complete remission
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author: Editorial comments.
• Please include the clinicaltrials.gov registry number after the abstract: http://clinicaltrials.gov/show/NCT01817426. Response: We have included the clinicaltrials.gov registry number after the abstract.
• STOP IT should be included in the title if this remains the name of the trial. Response: STOP IT remains a name for the study, and is now included as the short title.
• Please check through the English with editorial help or the assistance of a native English speaker. For example: ' Limited economic resources, and long-time safety, have warranted strategies for favorably discontinuation of IFX maintenance therapy in patients in remission.' is not clear. Response: The manuscript has been checked by a native English speaker, and has been revised accordingly.
• The endpoint is 48 weeks in the manuscript and one year in the registry; please explain the discrepancy in the manuscript. Response: The correct time for endpoints is 48 weeks (the period from inclusion until the patients last visit). The screening visit is 8 weeks prior to inclusion. We have corrected this discrepancy in the registry.
• 'We have not applied for approval of this study yet, and the study will only take place when approved by The Regional Committee on Health Research Ethics, subsequent to an application.' Response: We are uncertain about what the exact question is. The sentence (at the end of the section: 'course of study') refers to a rescue-study (i.e. a separate study, not a part of the STOP IT study) including patients who are randomized to discontinue IFX, relapse (and consequently withdrawn from the STOP IT study) and are then retreated with IFX. It is our intention that this study will be a retrospective observational study; we have not started this study. This separate study will not start before The Regional Committee on Health Research Ethics has approved it. We have revised the manuscript to stress this point. We hope that this addresses the point raised.
• Please see the SPIRIT statement (http://www.spirit-statement.org/) for a list of items that should be covered. For example, I didn't see information on how the randomisation would happen. Response: We have revised the manuscript according to the SPIRIT statement, and this has let to changes in the section 'Methods and analysis', 'Ethics and dissemination´, and 'Funding statement'. Changes are marked with red color. Of note, due to limited space in the manuscript, the SPIRIT items/ sections listed below are only available in the appendices to the full protocol: Item no 18a: Study instruments (questionnaires: IBDQ, CDAI, WPAI and SES-CD). Item no 29: Access to data. This is described in the cooperation agreement. At that time, the role of f-calprotectin in monitoring IBD patients was still debatable, the analysis was not readily available at all centers and a well-defined limit for remission had not been clearly established. Thus it was decided not to make f-calprotectin an integral part of the definition of remission. However, considering the mounting evidence of the clinical usefulness of f-calprotectin, this parameter will in the future be measured at every study visit. Data will be correlated to other measures of remission but will not be an integral part of the definition of remission in this study. This has been clarified in the revised manuscript. Please, see the section 'Endpoints' and Table 1. • MRI: the authors defined mucosal healing by no signs of disease activity. referecebces related to this point are not reliable with this definition. Report Ordas Study (gastroenetrology wich define mucosal healing with Maria Score. In the design, it is reported Endoscopy and / or MRI and in the beginning of study design: colonoscopy or MRI: clarify Response: Endoscopic examination will be performed in patients with disease in terminal ileum and colon. MRI is scheduled for patients with small bowel Crohn's disease, beyond terminal ileum. The selected modality (ileocolonoscopy, sigmoidoscopy, MRI) depends on the patient's last known disease location. We can not use the suggested Maria score, since it is only validated for disease in colon and terminal ileum, where we do endoscopy, which is the gold standard for assessment of mucosal healing. This has been clarified in the revised manuscript. Please, see the section 'Course of study'.
• Concomitant therapy with other immune suppressants is allowed. This point could biased resuts. We can think that descalation of IFX undercombotherpy (like STORI) is not the sale that descalation in patients treated by IFX monotherpy. This point must be discused. Strafie on IS? it could be a limitation of this study Response: We completely agree. In a recent protocol amendment, we added stratification based on concomitant immunosuppressive therapy (AZA, MP, MTX). We are very sorry that this was not explained in the first manuscript. Allocation will also be stratified for the existence of a history of fistulising disease. This has been clarified in the revised manuscript. Please, see the section 'Course of study'.
• Are patients optimised under IFX treatment included or only patients teated at 5mg/kg ? Response: Yes, patients receiving 5-10 mg/kg can be included in the study. This has been clarified in the revised manuscript. Please, see the section 'Study design and patients'.
• It will be very difficult to included the number of patients planned in this study. STORI study included all patients only in clinical remission under combotherapy for at least 6 months. In this study included all GETAID centers from France and some belgium centers), the time of inclusion was more than two yeras. In the study design, inclusion of patient with deep remission (clinical, biological and tissue) could be more difficult and a very large multicentric study could be usefull for perhaps obtain this number of patients. It is a very important trial. We ned to investigate how to manage patients with CD in long term sustained complete remission. Response: Thank you for your concern, which we share. Consequently, the study has now included 5 centers in Denmark and we are working on expanding the study to include centers in Norway, Sweden, Finland and Iceland. Furthermore, we have extended the inclusion period to November 2016. This has been clarified in the revised manuscript. Please, see the section 'Data analysis plan'.
